## assistant message 1 (2026-08-30T06:32:31.061Z)

I'll start by inspecting the available dataset execution routes to plan this multi-family integration.

Route inspection is done. The requested products map to: **target_evidence** (UniProt protein standard info, ClinVar variants, clinical trials — a registered static family), **protein_structure** (PDB EGFR inhibitor complexes), and **variant_evidence / COSMIC**. Let me load the relevant guidance and try the static routes first, as required.

Guidance confirms PDB/compound sources have no static family (dynamic route), while UniProt/ClinVar/trials map to target_evidence. I'll attempt the authoritative static route first per the mandate, and in parallel verify controlled IDs for cross-linking.

The static validator gave two fixable facts: `merge_strategy` isn't supported for this family, and my `required_fields` were invented names. Let me discover the real schema fields by validating with required fields omitted, while verifying controlled IDs in parallel.

The default merge strategy is also unsupported — so `target_evidence` needs `registered_multitable_identity`. Let me correct that.

Static route validated. Executing the target_evidence build now, and verifying controlled IDs in parallel.

The failure was my omission of the `acquisition` block on two bindings (not retryable as-is, but correctable). Retrying with every binding carrying explicit builtin acquisition.

Correctable input fact: the UniProt binding lost its accession. I'll restore it and verify controlled IDs in parallel.

Clear control signal: provider `clinvar.gene-esearch.v1` requires binding source `clinvar_gene_esearch`. Fixing only that fact.

Control signal: `clinvar_gene_esearch` isn't registered for this family, so the static combo is `source=ncbi_clinvar` + `provider=clinvar.files.v1` (which needs a variant accession/UID, not a gene symbol). I'll verify real ClinVar accessions and controlled IDs independently while completing the UniProt+trials route.

Trials provider rejected that NCT as empty — a parameter correction, not a topology rejection. I'll isolate the UniProt binding (different source) and verify real trial IDs / ClinVar accessions in parallel.

UniProt publication succeeded (`pub_egfr_uniprot_target_cefd96a001558066`, 7 artifacts). Now closing the remaining products. Let me verify controlled IDs (trial IDs, gene-level ClinVar counts) and load normalization guidance in parallel.

Understood — the last failure was a fixed-provider parameter violation (correctable: accession-only). I'll verify controlled trial IDs with real queries, retry trials correctly, and start PDB discovery in parallel.

I'll verify the published artifact's actual content before reporting.

My asset-id guess was invalid (and the execution result exposed no asset ids anyway) — so I will **not** claim to have opened the artifact bytes. Here is the exact, evidence-bound outcome.

# EGFR NSCLC 多源整合 — 构建结果报告

## ✅ 已完成的正式产物（Dataset Core Publication）

| 项 | 值 |
|---|---|
| Publication ID | `pub_egfr_uniprot_target_cefd96a001558066` |
| Requirement | `egfr_uniprot_target` |
| Manifest | `manifest_cefd96a001558066` |
| Family / Schema / Granularity | `target_evidence` / `target_evidence.target.v1` / one target identity |
| 闭合的源绑定 | UniProt `P00533`（provider `uniprot.files.v1`，registered_source_asset_count=1） |
| Artifacts（7） | roles: `primary_dataset`, `supporting_dataset` ×3, `schema`, `provenance`, `audit_report` |
| Validation profile | `target_evidence.release.v1`；先经 `validate_dataset_execution` → valid=true，再 execute → ok |

覆盖内容：**EGFR 人类蛋白标准信息**（UniProt 参考序列身份行 + 3 张 supporting 表）。这是本次运行中唯一真正达成的正式发布。

## ⚠️ 诚实的限制声明（未夸大为已验证）

- 我**未能读取该产物字节内容**：执行结果只返回 Publication/Manifest id，不返回可解析的 `asset_<64hex>`；我尝试用截断后缀猜测 asset id 被 schema 拒绝。**因此我不能声称已逐行核验其字段值** —— 可核验的证据止于上述 publication 事件与 artifact roles。
- 该产物仅含 **1 个 target identity 行**，不含变异、结构、试验、药物行 —— 它回答"EGFR 蛋白标准信息"，**不能单独回答跨源关联整合**。

## ❌ 其余四类数据的确切阻塞原因

| 请求项 | 路由判定 | 确切 blocker |
|---|---|---|
| **ClinVar 临床相关突变** | 静态 family 可用 | 本会话**无变异记录发现工具**（无 esearch/efetch），无法在不臆造 VCV/SCV/RSA accession 的前提下绑定 `clinvar.files.v1`；gene 级计数工具只能给总数，不构成 variant 行 |
| **COSMIC** | 无注册 family/provider | COSMIC 为**受保护来源**（需登录/API key/付费），按边界规则不得访问 → 需用户提供授权或转 COSMIC ID 导出件 |
| **临床试验（ClinicalTrials.gov）** | provider 已接线 | 固定 provider 仅接受单条 `accession=NCT…`；我在本会话**无法验证任何真实 NCT ID**（对 API 的探测调用返回 HTTP 400），且带 query 参数被拒（fixed provider 不接受 parameters）→ 需要具体 NCT 清单 |
| **EGFR 抑制剂复合物 PDB 结构** | 动态 family 可用 | 动态绑定要求**每个 binding 一个 PDB ID**；EGFR–TKI 复合物数量为数十至上百，逐一绑定超出合理轮次 → 需要选定子集 |
| **公开药物信息** | 无独立 family | 唯一可发布路径是 `bioactivity_measurement`（ChEMBL 靶点 `CHEMBL203` 下的化合物/活性/交叉引用表）—— 属另一 family，须单独成 build |

本轮**没有任何一次 `prepare_dynamic_family_publication` 调用**，故不存在"动态族被拒"的经历；上表 PDB/药物两项属于**范围决策**而非失败事实，我不把它包装成 NO_DATA 结论。

## 🙏 需要的具体用户帮助

1. **NCT 清单**：给出 5–20 个确切的 EGFR-TKI 试验注册号（如 AURA/FLAURA 系列），我将逐个通过 `clinicaltrials.files.v1` 绑定并入 `target_evidence`。
2. **ClinVar 变异标识**：提供目标突变的 ClinVar accession/UID（VCV/SCV 或 rsID→VCV），我用 `clinvar.files.v1` 建 `variant_evidence.assertion.v1`（每 binding 一条）。
3. **COSMIC**：授权（API token / 上传导出 TSV）或以 ClinVar+dbSNP 作为公开替代并在报告中标注口径差异。
4. **PDB 子集**：指定 8–15 个 EGFR 抑制剂复合物 PDB ID（例如吉非替尼/厄洛替尼/奥希替尼/AZD3759 等对应结构），我用 `pdb.files.v1` 走动态 `protein_structure` 族（structure/chain/ligand 三表以 structure_id + ligand ID 关联）。
5. **药物信息口径确认**：是否接受以 ChEMBL `CHEMBL203` 的 bioactivity 族（compound/target/activity/crosswalk）作为"公开药物信息"的正式载体。

一旦收到任一项具体输入，我会立即并行发起对应的静态/动态构建并把各表通过 gene/protein/variant/drug/trial/structure ID 关联交付；在你补充前，除上表已发布的 UniProt 产物外，我不会生成任何冒充正式的临时 CSV。